USO - Texas Oncology Trials

USO - Texas Oncology	Welcome, Profile Billing Logout

33 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Falkson, Carla I

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma

01/28

05/35

OFSET, NCT05879926: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

3960

Canada, US, RoW

Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression

NRG Oncology, National Cancer Institute (NCI)

Breast Cancer

01/32

07/34

Sanchez, Katherine

PREVENTABLE, NCT04262206: Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

Recruiting

20000

Atorvastatin 40 Mg Oral Tablet, Lipitor, Placebo oral tablet

Duke University, National Institute on Aging (NIA), National Heart, Lung, and Blood Institute (NHLBI), Wake Forest University Health Sciences

Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases

12/26

ELEGANT, NCT06492616: A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Recruiting

4220

Europe, Canada, US, RoW

Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen

Stemline Therapeutics, Inc.

Breast Cancer

08/29

10/32

POPB-TOX, NCT03198702: Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy

Recruiting

Europe

Botulinum toxin type A injection, Sham

University Hospital, Brest

Obstetrical Brachial Plexus Palsy

04/25

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

neoHIP, NCT03747120: Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]

Active, not recruiting

138

Paclitaxel, Taxol, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Pembrolizumab, Keytruda

University of Texas Southwestern Medical Center, Merck Sharp & Dohme LLC, Breast Cancer Research Foundation

HER2-positive Breast Cancer, Breast Cancer

11/24

12/29

CVRRC, NCT05772221: The Role of Social Determinants in Cardiovascular Health and Vascular Function

Recruiting

N/A

100

Screening

Baylor Research Institute, University of Texas-Arlington

Social Determinants of Health, Major Depressive Disorder, Cardiovascular Diseases

12/23

BEGIN, NCT06272864: BostonGene and Exigent Genomic INsight Study

Recruiting

N/A

400

BostonGene, Exigent

Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma

01/26

01/28

TAPS-ESP, NCT05476588: Tobacco, Alcohol, Prescription Drug, and Illicit Substance Use- Electronic Spanish Platform

Enrolling by invitation

N/A

1000

Screening

Baylor Research Institute, COG Analytics

Tobacco Use, Alcohol Abuse, Prescription Drug Abuse, Substance Use

05/25

TEACH, NCT06868498: Train and EMPOWER a Community Health Workforce to Achieve Equity and Reduce Disparities in Mental Health

Enrolling by invitation

N/A

1500

A semester-long course for training of students as CHWs with additional EMPOWER training for delivering a brief trans-diagnostic psychosocial intervention.

Baylor Research Institute, National Institute on Minority Health and Health Disparities (NIMHD), The University of Texas at Arlington

CHW Certification

05/28

12/29

Tedesco, Karen

FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Recruiting

750

Europe, US

Placebo, GLSI-100

Greenwich LifeSciences, Inc.

Breast Cancer

12/26

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry

Active, not recruiting

N/A

3465

Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test

Biotheranostics, Inc.

Breast Cancer

12/28

FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting

N/A

30000

Europe, Canada, US, RoW

MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint

Agendia

Breast Cancer

04/37

12/37

Ward, Patrick

FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Recruiting

750

Europe, US

Placebo, GLSI-100

Greenwich LifeSciences, Inc.

Breast Cancer

12/26

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

FISSH, NCT03677102: Fluids in Septic Shock

Recruiting

2/3

1096

Canada, RoW

higher chloride crystalloid, lower chloride crystalloid

McMaster University, The Physicians' Services Incorporated Foundation, Canadian Institutes of Health Research (CIHR)

Sepsis, Septic Shock

11/25

03/26

KEYNOTE B81, NCT04609566: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Active, not recruiting

142

Canada, US

brentuximab vedotin, ADCETRIS, pembrolizumab, KEYTRUDA®

Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC

Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck

12/29

NCT06431048: No DIET Trial: Dogmatic Interruption of Enteral NuTrition

Enrolling by invitation

N/A

120

Naso-enteral nutrition will be stopped when the patient is called to the OR for scheduled procedure., Naso-enteral nutrition will be stopped 2 hours before the scheduled procedure.

Jeffrey Coughenour

Gastrostomy, Tracheostomy

06/25

09/25

MYLUNG, NCT05885698: Consortium Part 3: Observational Study

Recruiting

N/A

7500

US Oncology Research

Carcinoma, Non-Small-Cell Lung

12/30

FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting

N/A

30000

Europe, Canada, US, RoW

MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint

Agendia

Breast Cancer

04/37

12/37

Benjamin, Sam

NRG-BR003, NCT02488967: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Active, not recruiting

782

Canada, US

Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat

NRG Oncology, National Cancer Institute (NCI)

Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma

10/26

S2206, NCT06058377: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Recruiting

3680

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Genetic Testing, Genetic Analysis, Genetic Examination, Genetic Test, Mammography, MG, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment

National Cancer Institute (NCI)

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma

05/26

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

01/28

05/35

Kodali, Dhatri

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry

Active, not recruiting

N/A

3465

Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test

Biotheranostics, Inc.

Breast Cancer

12/28

FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting

N/A

30000

Europe, Canada, US, RoW

MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint

Agendia

Breast Cancer

04/37

12/37

Sharma, Ruby

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

McNulty, Brendan

SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting

1016

Europe, Canada, Japan, US, RoW

LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed

Eli Lilly and Company, Loxo Oncology, Inc.

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

10/26

10/29

Lung-Map Screening Study, NCT03851445: Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Recruiting

2/3

10000

Screening Platform

SWOG Cancer Research Network, National Cancer Institute (NCI)

Previously Treated Non-Small Cell Lung Cancer

01/29

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Falkson, Carla I

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

01/28

05/35

Recruiting

3960

Canada, US, RoW

Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression

NRG Oncology, National Cancer Institute (NCI)

Breast Cancer

01/32

07/34

Sanchez, Katherine

PREVENTABLE, NCT04262206: Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

Recruiting

20000

Atorvastatin 40 Mg Oral Tablet, Lipitor, Placebo oral tablet

Duke University, National Institute on Aging (NIA), National Heart, Lung, and Blood Institute (NHLBI), Wake Forest University Health Sciences

Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases

12/26

ELEGANT, NCT06492616: A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Recruiting

4220

Europe, Canada, US, RoW

Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen

Stemline Therapeutics, Inc.

Breast Cancer

08/29

10/32

POPB-TOX, NCT03198702: Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy

Recruiting

Europe

Botulinum toxin type A injection, Sham

University Hospital, Brest

Obstetrical Brachial Plexus Palsy

04/25

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

neoHIP, NCT03747120: Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]

Active, not recruiting

138

Paclitaxel, Taxol, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Pembrolizumab, Keytruda

University of Texas Southwestern Medical Center, Merck Sharp & Dohme LLC, Breast Cancer Research Foundation

HER2-positive Breast Cancer, Breast Cancer

11/24

12/29

CVRRC, NCT05772221: The Role of Social Determinants in Cardiovascular Health and Vascular Function

Recruiting

N/A

100

Screening

Baylor Research Institute, University of Texas-Arlington

Social Determinants of Health, Major Depressive Disorder, Cardiovascular Diseases

12/23

BEGIN, NCT06272864: BostonGene and Exigent Genomic INsight Study

Recruiting

N/A

400

BostonGene, Exigent

Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma

01/26

01/28

TAPS-ESP, NCT05476588: Tobacco, Alcohol, Prescription Drug, and Illicit Substance Use- Electronic Spanish Platform

Enrolling by invitation

N/A

1000

Screening

Baylor Research Institute, COG Analytics

Tobacco Use, Alcohol Abuse, Prescription Drug Abuse, Substance Use

05/25

TEACH, NCT06868498: Train and EMPOWER a Community Health Workforce to Achieve Equity and Reduce Disparities in Mental Health

Enrolling by invitation

N/A

1500

A semester-long course for training of students as CHWs with additional EMPOWER training for delivering a brief trans-diagnostic psychosocial intervention.

Baylor Research Institute, National Institute on Minority Health and Health Disparities (NIMHD), The University of Texas at Arlington

CHW Certification

05/28

12/29

Tedesco, Karen

FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Recruiting

750

Europe, US

Placebo, GLSI-100

Greenwich LifeSciences, Inc.

Breast Cancer

12/26

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry

Active, not recruiting

N/A

3465

Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test

Biotheranostics, Inc.

Breast Cancer

12/28

FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting

N/A

30000

Europe, Canada, US, RoW

MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint

Agendia

Breast Cancer

04/37

12/37

Ward, Patrick

FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Recruiting

750

Europe, US

Placebo, GLSI-100

Greenwich LifeSciences, Inc.

Breast Cancer

12/26

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

FISSH, NCT03677102: Fluids in Septic Shock

Recruiting

2/3

1096

Canada, RoW

higher chloride crystalloid, lower chloride crystalloid

McMaster University, The Physicians' Services Incorporated Foundation, Canadian Institutes of Health Research (CIHR)

Sepsis, Septic Shock

11/25

03/26

KEYNOTE B81, NCT04609566: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Active, not recruiting

142

Canada, US

brentuximab vedotin, ADCETRIS, pembrolizumab, KEYTRUDA®

Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC

Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck

12/29

NCT06431048: No DIET Trial: Dogmatic Interruption of Enteral NuTrition

Enrolling by invitation

N/A

120

Naso-enteral nutrition will be stopped when the patient is called to the OR for scheduled procedure., Naso-enteral nutrition will be stopped 2 hours before the scheduled procedure.

Jeffrey Coughenour

Gastrostomy, Tracheostomy

06/25

09/25

MYLUNG, NCT05885698: Consortium Part 3: Observational Study

Recruiting

N/A

7500

US Oncology Research

Carcinoma, Non-Small-Cell Lung

12/30

FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting

N/A

30000

Europe, Canada, US, RoW

MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint

Agendia

Breast Cancer

04/37

12/37

Benjamin, Sam

NRG-BR003, NCT02488967: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Active, not recruiting

782

Canada, US

NRG Oncology, National Cancer Institute (NCI)

10/26

S2206, NCT06058377: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Recruiting

3680

National Cancer Institute (NCI)

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma

05/26

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

01/28

05/35

Kodali, Dhatri

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry

Active, not recruiting

N/A

3465

Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test

Biotheranostics, Inc.

Breast Cancer

12/28

FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting

N/A

30000

Europe, Canada, US, RoW

MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint

Agendia

Breast Cancer

04/37

12/37

Sharma, Ruby

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

McNulty, Brendan

SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting

1016

Europe, Canada, Japan, US, RoW

LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed

Eli Lilly and Company, Loxo Oncology, Inc.

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

10/26

10/29

Lung-Map Screening Study, NCT03851445: Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Recruiting

2/3

10000

Screening Platform

SWOG Cancer Research Network, National Cancer Institute (NCI)

Previously Treated Non-Small Cell Lung Cancer

01/29

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites